Volume 121, Issue 5 , Pages 1140-1147.e2, May 2008
Surfactant protein D alters allergic lung responses in mice and human subjects
Background
Surfactant protein (SP) D has been proposed to be protective in allergic airway responses.
Objective
We aimed to determine the effect of SP-D deficiency on murine and human airway allergy.
Methods
Immunologic responses of SP-D gene–deficient mice (Sftpd−/−) at baseline and after 4 intranasal Aspergillus fumigatus exposures were assessed. In addition, the significance of a single nucleotide polymorphism (Met11Thr) in the human SP-D gene (known to decrease SP-D function) was investigated.
Results
Macrophage and neutrophil bronchoalveolar lavage fluid levels and large airway mucus production were increased in naive Sftpd−/− mice in association with increased lung CCL17 levels and CD4+ T cell numbers. TH2-associated antibody levels (IgG1 and IgE) were significantly lower in 4- to 5-week-old Sftpd−/− mice (P < .05). Accordingly, naive Sftpd−/− splenocytes released significantly less IL-4 and IL-13 on anti-CD3/CD28 stimulation (P < .01). After intranasal allergen exposures, a modest decrease in bronchoalveolar lavage fluid eosinophilia and IL-13 levels was observed in Sftpd−/− mice compared with values seen in wild-type mice in association with decreased airway resistance (P < .01). A single nucleotide polymorphism in the SFTPD gene, affecting SP-D levels and pathogen binding, was associated with decreased atopy in black subjects and potentially lower asthma susceptibility in white subjects.
Conclusion
Sftpd−/− mice have an impaired systemic TH2 response at baseline and reduced inflammation and airway responses after allergen exposure. Translational studies revealed that a polymorphism in the SFTPD gene was associated with lower atopy and possibly asthma susceptibility. Taken together, these results support the hypothesis that SP-D–dependent innate immunity influences atopy and asthma.
Key words: Allergy, lung, surfactant protein D, polymorphism, eosinophil, IL-13, Aspergillus, endotoxin
Abbreviations used: BALF, Bronchoalveolar lavage fluid, PAS, Periodic acid-Schiff, SNP, Single nucleotide polymorphism, SP, Surfactant protein, Sftpd−/−, Surfactant protein D gene–deficient mice, TARC, Thymus and activation-regulated chemokine
Supported in part by a grant from the Mechanism of Asthma and Allergic Inflammation (MAAI) 2005 Interest Section Award (E.B.B.), MECEH-Institutional NIEHS T32 ES10957-03 and CCHMC-Institutional NICHD T32 HD43005-01 grants (M.D.S.), as well as National Institutes of Health grants HL-63329 (J.A.W.), R01 AI42242, HL-076383, and AI057803 (M.E.R.).
Disclosure of potential conflict of interest: N. Wang has received research support from the National Institutes of Health. J. A. Whitsett has a US patent (no. 6,838,429; surfactant protein D and emphysema), has received research support from the National Institutes of Health; and is on the speakers' bureau for Abbott Laboratories. M. E. Rothenberg has consulting arrangements with Ception Therapeutics, GlaxoSmith-Kline, and MedaCorp; owns stock in Ception Therapeutics; is on the speakers' bureau for Merck; and has received honoraria from GlaxoSmithKline, Ception Therapeutics, and Merck. The rest of the authors have declared that they have no conflict of interest.
PII: S0091-6749(08)00361-8
doi:10.1016/j.jaci.2008.02.011
© 2008 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Volume 121, Issue 5 , Pages 1140-1147.e2, May 2008
